Carmat Valuation
Is ALCAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALCAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ALCAR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALCAR's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALCAR?
Key metric: As ALCAR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ALCAR's PS Ratio? | |
|---|---|
| PS Ratio | 6.9x |
| Sales | €6.93m |
| Market Cap | €50.70m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 14.1x |
| Enterprise Value/EBITDA | -1.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ALCAR's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.7x | ||
ALKLH Klea Holding | 3.5x | n/a | €52.9m |
ALSMA S.M.A.I.O | 1.9x | 27.6% | €13.2m |
ALCOR Biocorp Production | 12.1x | 47.9% | €154.5m |
AMPLI Amplitude Surgical | 1.4x | n/a | €149.7m |
ALCAR Carmat | 7.3x | 52.5% | €50.7m |
Price-To-Sales vs Peers: ALCAR is expensive based on its Price-To-Sales Ratio (6.9x) compared to the peer average (2.2x).
Price to Sales Ratio vs Industry
How does ALCAR's PS Ratio compare vs other companies in the FR Medical Equipment Industry?
Price-To-Sales vs Industry: ALCAR is expensive based on its Price-To-Sales Ratio (6.9x) compared to the European Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is ALCAR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALCAR's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.13 | €8.27 +632.9% | 53.3% | €18.00 | €5.30 | n/a | 6 |
| Nov ’25 | €1.46 | €8.27 +466.2% | 53.3% | €18.00 | €5.30 | n/a | 6 |
| Oct ’25 | €1.31 | €8.27 +530.1% | 53.3% | €18.00 | €5.30 | n/a | 6 |
| Sep ’25 | €2.48 | €11.18 +351.7% | 40.1% | €18.00 | €6.80 | n/a | 5 |
| Aug ’25 | €2.60 | €11.18 +330.0% | 40.1% | €18.00 | €6.80 | n/a | 5 |
| Jul ’25 | €2.43 | €12.33 +407.2% | 35.8% | €18.00 | €6.80 | n/a | 4 |
| Jun ’25 | €3.15 | €12.33 +291.3% | 35.8% | €18.00 | €6.80 | n/a | 4 |
| May ’25 | €3.01 | €14.22 +372.4% | 24.4% | €18.00 | €9.00 | n/a | 5 |
| Apr ’25 | €4.12 | €14.22 +245.6% | 24.4% | €18.00 | €9.00 | n/a | 5 |
| Mar ’25 | €4.13 | €14.22 +244.3% | 24.4% | €18.00 | €9.00 | n/a | 5 |
| Feb ’25 | €4.23 | €14.22 +236.2% | 24.4% | €18.00 | €9.00 | n/a | 5 |
| Jan ’25 | €6.70 | €18.88 +181.8% | 15.2% | €22.00 | €14.50 | n/a | 6 |
| Dec ’24 | €3.63 | €18.88 +420.2% | 15.2% | €22.00 | €14.50 | n/a | 6 |
| Nov ’24 | €4.09 | €18.88 +362.3% | 15.2% | €22.00 | €14.50 | €1.46 | 6 |
| Oct ’24 | €4.64 | €19.62 +322.8% | 8.7% | €22.00 | €17.00 | €1.31 | 5 |
| Sep ’24 | €6.85 | €24.10 +251.8% | 13.4% | €28.00 | €20.00 | €2.48 | 4 |
| Aug ’24 | €7.28 | €25.68 +252.7% | 16.7% | €32.00 | €20.00 | €2.60 | 5 |
| Jul ’24 | €7.21 | €25.68 +256.2% | 16.7% | €32.00 | €20.00 | €2.43 | 5 |
| Jun ’24 | €7.30 | €25.68 +251.8% | 16.7% | €32.00 | €20.00 | €3.15 | 5 |
| May ’24 | €8.53 | €25.68 +201.1% | 16.7% | €32.00 | €20.00 | €3.01 | 5 |
| Apr ’24 | €9.61 | €27.24 +183.5% | 12.0% | €32.00 | €22.00 | €4.12 | 5 |
| Mar ’24 | €9.22 | €27.44 +197.6% | 10.7% | €32.00 | €23.00 | €4.13 | 5 |
| Feb ’24 | €10.75 | €27.44 +155.3% | 10.7% | €32.00 | €23.00 | €4.23 | 5 |
| Jan ’24 | €10.43 | €27.26 +161.4% | 10.7% | €32.00 | €23.00 | €6.70 | 5 |
| Dec ’23 | €14.26 | €29.00 +103.4% | 14.6% | €35.00 | €23.00 | €3.63 | 5 |
| Nov ’23 | €12.52 | €29.00 +131.6% | 14.6% | €35.00 | €23.00 | €4.09 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
bioMérieux
€11.5b
Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
BIM
€97.50
7D
-3.8%
1Y
0.3%
Laboratoires Euromedis Société anonyme
€13.0m
Through its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand name for healthcare professionals, local communities, and individuals in France and internationally.
ALEMG
€4.57
7D
-4.2%
1Y
-3.8%
emeis Société anonyme
€901.5m
Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.
EMEIS
€5.60
7D
-10.5%
1Y
-98.3%